FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Clinical trials for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) explained in plain language.
Never miss a new study
Get alerted when new FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) trials appear
Sign up with your email to follow new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising drug combo may tame rare bone disease flares
Disease control Recruiting nowThis study looks at whether anti-IL1 medications (like anakinra or canakinumab) can reduce painful flare-ups and abnormal bone growth in people with fibrodysplasia ossificans progressiva (FOP), a rare genetic condition. About 11 participants with severe FOP will be tracked before…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
Promising new drug aims to halt rare bone disease FOP
Disease control Recruiting nowThis study tests an experimental drug called INCB000928 in people with fibrodysplasia ossificans progressiva (FOP), a rare condition where soft tissues turn into bone. The goal is to see if the drug can prevent or reduce new abnormal bone growth. About 98 participants aged 2 and …
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Worldwide FOP database launches to unlock secrets of rare bone disorder
Knowledge-focused Recruiting nowThis study creates a global online registry for people with Fibrodysplasia Ossificans Progressiva (FOP), a rare condition where soft tissues turn into bone. Participants and their doctors can securely report symptoms, flare-ups, and mobility changes over time. The goal is to gath…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
Sponsor: The International FOP Association • Aim: Knowledge-focused
Last updated May 18, 2026 12:00 UTC